Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 1, 2011, Pages 91-97

  Yilmaz, Yusuf ^a   Yonal, Oya ^a   Kurt, Ramazan ^a   Alahdab, Yesim Ozen ^a   Eren, Fatih ^b   Ozdogan, Osman ^a   Celikel, Cigdem Ataizi ^a   Imeryuz, Nese ^a   Kalayci, Cem ^a   Avsar, Erol ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Adipokines; Enzyme linked immunosorbent assay; Liver fibrosis; Nonalcoholic fatty liver disease

Indexed keywords

ADIPSIN; ALCOHOL; C REACTIVE PROTEIN; CHEMERIN; OMENTIN; PEPTIDE HYDROLASE; UNCLASSIFIED DRUG;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BIOPSY; CASE-CONTROL STUDIES; CHEMOKINES; COMPLEMENT FACTOR D; CYTOKINES; FATTY LIVER; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED;

EID: 78651368690     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.516452     Document Type: Article

References (30)

1. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50:S412-16.
2. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171-80.
3. Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009;8:S18-24.
4. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009;116:539-64.
5. Grønbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2008;2:705-11.
6. Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009;42:802-7.
7. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010;314:1-16.
8. Kobayashi K. Adipokines: therapeutic targets for metabolic syndrome. Curr Drug Targets 2005;6:525-9.
9. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-69.
10. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;9:299-314.
11. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-21.
12. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670.
13. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290: E1253-61.
14. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29-33.
15. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655-61.
16. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Bio-phys Res Commun 2007;362:1013-18.
17. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. ScandJGastroenterol 2010; 45:235-42.
18. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2010;95:2892-6.
19. Sniderman AD, Cianflone K. The adipsin-acylation-stimulating protein pathway and microenvironmental meta-bolic regulation. World Rev Nutr Diet 1997;80:44-81. (Pubitemid 127029287)
20. Gabrielsson BG, Johansson JM, Lönn M, Jernås M, Olbers T, Peltonen M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res 2003;11:699-708.
21. Fain JN, Nesbit AS, Sudlow FF, Cheema P, Peeples JM, Madan AK, et al. Release in vitro of adipsin, vascular cell adhesion molecule 1, angiotensin 1-converting enzyme, and soluble tumor necrosis factor receptor 2 by human omental adipose tissue as well as by the nonfat cells and adipocytes. Metabolism 2007;56:1583-90.
22. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Associa-tion Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006;29:1955-62.
23. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syn-drome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scien-tific issues related to definition. Circulation 2004;109:433-8.
24. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
25. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-7.
26. Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, et al. Hepatocellular ballooning in NASH. J Hepatol 2010; doi:10.1016/j.jhep.2010.04. 031.
27. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepa-titis in obesity. Hepatology 2008;48:2086-7.
28. Yilmaz Y, Dolar E. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: tools or decora-tions? World J Gastroenterol 2009;15:4346-7.
29. Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 frag-ments and biomarkers of the metabolic syndrome in nonal-coholic steatohepatitis. World J Gastroenterol 2009;15: 4387-91.
30. Kos K, Wilding JP. Adipokines: emerging therapeutic tar-gets. Curr Opin Investig Drugs 2009;10:1061-8.